SCHEMBL312428

SCHEMBL312428

Nc1cccc2nc[nH]c12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 6/20 0.43
KDM4E B2RXH2 5/20 0.42
MAPT P10636 3/20 0.42
ALDH1A1 P00352 3/20 0.42
APEX1 P27695 1/20 0.42
RECQL P46063 1/20 0.42
BLM P54132 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
AXL P30530 1/20 0.41
PDPK1 O15530 2/20 0.39
CA12 O43570 1/20 0.39
ALOX15 P16050 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CA9 Q16790 1/20 0.39
TNKS2 Q9H2K2 1/20 0.39
PRKCI P41743 1/20 0.39
RAD52 P43351 1/20 0.38
HSD17B10 Q99714 2/20 0.36
PI4KA P42356 2/20 0.36
PI4K2B Q8TCG2 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30036694 1.00 PARP1 (0.43) PARP1KDM4EMAPTALDH1A1APEX1
Hydrochloric Acid SCHEMBL5789385 0.98 PARP1 (0.42) PARP1KDM4EMAPTALDH1A1APEX1
Hydrochloric Acid SCHEMBL13387353 0.98 PARP1 (0.42) PARP1KDM4EMAPTALDH1A1APEX1
SCHEMBL29395343 0.79 AXL (0.35) PARP1KDM4EMAPTALDH1A1BLM
SCHEMBL196912 0.77 PARP1 (0.42) PARP1KDM4EALDH1A1PDPK1CA12
SCHEMBL3232202 0.76 PARP1 (0.41) PARP1KDM4EMAPTALDH1A1PDPK1
SCHEMBL196737 0.74 PARP1 (0.56) PARP1MAPTRECQLPDPK1CA12
SCHEMBL1445123 0.74 PDPK1 (0.41) PARP1KDM4EMAPTALDH1A1TDP1
SCHEMBL1019602 0.74 QPCT (0.42) PARP1KDM4EMAPTALDH1A1RECQL
SCHEMBL4130388 0.74 PARP1 (0.56) PARP1KDM4EMAPTALDH1A1PDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630851-B2 Polynucleotide modification methods OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2026-05-19 US claimed
US-12624387-B2 Method for reducing primer dimer formation and increasing amplification efficiency SEEGENE, INC. (KR) 2026-05-12 US claimed
US-12584168-B2 Sample preparation method OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2026-03-24 US claimed
US-12371736-B2 TD probe and its uses SEEGENE, INC. (KR) 2025-07-29 US claimed
CN-119978548-A Ammonium polyphosphate flame retardant and preparation method and application thereof 青岛科技大学 2025-05-13 CN claimed
CN-119735921-A Basalt fiber reinforced anti-falling mobile phone shell and preparation method thereof 安徽简星科技有限公司 2025-04-01 CN claimed
CN-119571331-A Corrosion inhibitor for petroleum refining distillation device and preparation method thereof 新疆建咨中亿石油化工有限公司 2025-03-07 CN claimed
CN-118874529-A Efficient glass fiber denitration catalyst and preparation method and application thereof 安徽通普材料科技有限公司 2024-11-01 CN claimed
WO-2024136630-A1 METHOD FOR SEQUENCE HOMOLOGY SEARCH OF NUCLEOTIDE DATABASE 주식회사 씨젠 2024-06-27 WO claimed
CN-117181990-B High-temperature-resistant precoated sand and preparation method thereof 胜利油田金岛实业有限责任公司 2024-03-19 CN claimed
EP-0599703-B1 Use of 4-hydroxy- or 4-aminobenzumidazol or their derivatives as coupler agent in oxidative dye compositions, the compositions and its method of application OREAL (FR) 1997-09-17 EP claimed
EP-0728464-B1 Composition for dyeing keratinous fibers comprising a diaminopyrazole derivative and a heterocyclic coupleur and dyeing process OREAL (FR) 1997-07-30 EP claimed
EP-0605320-B1 Dye composition for keratinic fibres based on paraphenylenediamine, metaphenylenediamines and benzimidazol derivates, and the dyeing process using same OREAL (FR) 1997-04-09 EP claimed
US-5578087-A Dyeing compositions for keratinous fibres based on para-phenylene-diamines, meta-phenylenediamine and benzimidazole derivatives, and dyeing process employing them L'OREAL (FR) 1996-11-26 US claimed
EP-0728466-A1 Keratinous fibers oxidation dyeing composition comprising an oxidation base, an indolic coupler and an additional heterocyclic coupler and dyeing process L'OREAL (FR) 1996-08-28 EP claimed
EP-0728464-A1 Composition for dyeing keratinous fibers comprising a diaminopyrazole derivative and a heterocyclic coupleur and dyeing process L'OREAL (FR) 1996-08-28 EP claimed
US-5494490-A DYEING KERATINOUS FIBERS BY APPLYING AS COUPLER 4-HYDROXY- OR 4-AMINOBENZIMIDAZOLE OR THEIR DERIVATIVES IN PRESENCE OF PARA-PHENYLENEDIAMINE OR ITS DERIVATIVES L'OREAL (FR) 1996-02-27 US claimed
EP-0605320-A1 Dye composition for keratinic fibres based on paraphenylenediamine, metaphenylenediamines and benzimidazol derivates, and the dyeing process using same L'OREAL (FR) 1994-07-06 EP claimed
EP-0599703-A1 Use of 4-hydroxy- or 4-aminobenzumidazol or their derivatives as coupler agent in oxidative dye compositions, the compositions and its method of application L'OREAL (FR) 1994-06-01 EP claimed
US-4662905-A REACTION PRODUCT OF COPPER SALT AND AN IMIDAZOLE, PYRAZOLE, TRIAZOLE, OR TETRAZOLE Itaru Todoriki, Director of Agency of Industrial Science and Technology (JP) 1987-05-05 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12584168-B2 Sample preparation method POLN, POLRMT, POLM PARP1 53/4885KDM4E 4275/4885MAPT 3486/4885
US-12630851-B2 Polynucleotide modification methods PNP, NT5C3B, UNG PARP1 155/4885KDM4E 1727/4885MAPT 3328/4885
US-12624387-B2 Method for reducing primer dimer formation and increasing amplification efficiency UBR4, UBAP2, UBAP2L PARP1 385/4885KDM4E 3690/4885MAPT 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.